01 Integration of Trabecular Bone Score into DXA Workstations for Improved Fracture-Risk Stratification Bone densitometer devices market analysis shows that manufacturers are integrating trabecular bone score (TBS) technology into dual-energy X-ray absorptiometry (DXA) workflows to improve skeletal assessment. This transition is strengthening the role of advanced DXA systems in osteoporosis assessment and clinical fracture-risk stratification. Medimaps Group’s TBS iNsight software analyzes lumbar spine DXA images to provide information about trabecular bone texture that complement conventional bone density results. Adoption of Opportunistic Bone Density Measurement from Routine CT Scans Adoption of routine computed tomography (CT) scans for opportunistic bone health assessment is changing how healthcare providers identify patients at risk of osteoporosis. This approach is expanding osteoporosis screening beyond dedicated bone densitometry appointments and helps to identify patients who remain undiagnosed. AI-based software analyzes vertebral attenuation on routine abdominal CT scans to flag patients who require a formal osteoporosis assessment.
01 Supply chain disruptions are expected to have a moderate impact on the bone densitometer devices market share due to dependence on X-ray detectors, electronic components, imaging sensors, specialized materials, and precision manufacturing equipment. The market is likely to follow an S-shaped recovery, with gradual restoration of component supplies and manufacturing operations. Supply chain constraints could reduce market growth by 1.0–1.5 percentage points, lowering the CAGR of 5.8% to around 4.3%–4.8%. As supply conditions normalize through diversified sourcing, the bone densitometer devices market growth is expected to stabilize.
01 The bone densitometer devices market forecasts strategic investment activity driven by advances in bone density measurement technologies, growing demand for osteoporosis screening, and the expansion of preventive healthcare services. Key Investment and Funding Activities in Bone Densitometer Devices Market, 2026 Company Value (USD) Details Osteoboost Health USD 8 million In April 2026, Osteoboost Health closed an USD 8 million financing round to scale manufacturing, expand clinical research, and increase commercial access to its FDA-cleared wearable medical device for women with low bone density. Diagnostic Medical Systems (DMS Group) Up to USD 23 million equivalent In March 2026, DMS Group announced a financing facility of up to EUR 20 million from the European Investment Bank, supported by the European Union's InvestEU program.
01 Demand for Bone Density Screening During Glucocorticoid Therapy and Aromatase Inhibitor Treatment Drives Market Long-term glucocorticoid therapy for conditions such as rheumatoid arthritis and systemic lupus erythematosus increases the risk of bone loss and fragility fractures. Healthcare providers use dual-energy X-ray absorptiometry (DXA) to assess bone mineral density and guide osteoporosis prevention and treatment, supporting demand for bone densitometer devices among hospitals and diagnostic centers.Aromatase inhibitor treatment for hormone receptor-positive breast cancer accelerates bone loss, creating a need for regular bone mineral density assessment. Oncologists use DXA scans to establish baseline bone health and monitor treatment-associated changes, supporting device utilization across oncology clinics and diagnostic facilities.